Skip to content

Evaluate the safety and efficacy of Ankura ?stent graft for the treatment of aortic endovascular: a prospective, multi-center, randomized clinical trial

Evaluate the safety and efficacy of Ankura ?stent graft for the treatment of aortic endovascular: a prospective, multi-center, randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002844
Enrollment
Unknown
Registered
2012-11-14
Start date
2012-11-30
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic aortic aneurysm,Thoracoabdominal aortic aneurysm and Aortic dissection

Interventions

Test group:Using Ankura ? stent graft system for the treatment
Control group:Using Ankura stent graft system for the treatment

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged >=18 years; 2) The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial; 3) The patient is diagnosed with aortic dissection of Standford B; 4) The patient is diagnosed with thoracic aortic aneurysm, the anchoring area distance left subclavian artery >= 20mm (or the anchoring area distance left common carotid artery>=20mm and the left vertebral artery isn't the advantage artery); Distal distance the celiac artery >=20mm; The diameter of aneurysm neck is between 20mm and 42mm; 5) The patient with at least 1 years survival expectancy.

Exclusion criteria

Exclusion criteria: 1) Female patients in pregnancy or lactation; 2) The Patient had aorta surgical repair or cavity history of surgical treatment; 3) The Patient had sufferred myocardial infarction or stroke within 3 months before screening; 4) The Patient suffers form connective tissue disease or activity systemic infection; 5) The Patient has severe coagulation diaorders.

Design outcomes

Primary

MeasureTime frame
The incidence of 30 days without major equipment related adverse events;

Countries

China

Contacts

Public ContactChang Shu
changshu01@yahoo.com+86 731 85295832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026